Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 25 of 41
Quincy Family, Youth & Technology For Lifestyle Change (FYT-4-LIFE) Study
NCT02324361
Efficacy Study on Silver-coated ETT Cleaned With a Novel Device
NCT02120001
Light Therapy for Moderate Traumatic Brain Injury
NCT02233413
The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas
NCT02105324
Connect 4 Health: An Intervention to Improve Childhood Obesity Outcomes
NCT02124460
Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe
NCT02210039
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
NCT02169219
The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness
NCT02209259
Effects of Frailty, Sarcopenia and Muscle Wasting on Outcomes of Patients in the Surgical Intensive Care Unit
NCT02270502
Determination of the Predictors of Nocturnal Desaturation in Postpartum Women
NCT02330055
Use of Negative Pressure Wound Therapy in High Risk Surgical Closed Incisions
NCT02137447
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02096952
Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)
NCT02091232
L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults
NCT01853280
Neuropeptides in Human Reproduction
NCT01952782
A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas
NCT02092220
The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults
NCT02057263
Evaluation of Mind-body Educational Program to Enhance Resiliency and Reduce Burnout in First Year Residents
NCT02621788
PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients
NCT02130271
A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder
NCT01914939
International Latino Research Partnership
NCT02038855
Dietary Intake and Circulating Levels of Branched Chain Amino Acids
NCT02110602
Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT
NCT02086513
The Impact of a "Serious Game" on Improving Patient's Medication Knowledge
NCT01786044
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
NCT02298270
Pain Management in Cancer Patients Using a Mobile Application
NCT02069743
Pulmonary Perfusion Heterogeneity in Patients With CTEPH Using Functional PET Imaging
NCT02114047
FMISO PET Study of Glioblastoma
NCT02076152
Abiraterone Acetate for Castrate Resistant Prostate Cancer
NCT01961843
The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures
NCT01969227
Text Messaging Adherence to Stimulant Medication
NCT01967485
Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
NCT01978743
Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders
NCT02357290
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
NCT01929759
Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women
NCT02040532
Randomized Trial of Financial Incentives to Reduce Sugar-sweetened Beverage Purchases by Low-income, Latino Families
NCT01990508
Neck Fat Accumulation and Its Relationship to Cardiovascular Risk and Metabolic Syndrome
NCT02205021
Cholecalciferol Supplementation for Sepsis in the ICU
NCT01896544
Ensuring Communication in Hospice by Oncology Study (ECHO)
NCT02069769
MET-PET for Newly Diagnosed Glioblastoma
NCT01867593
Hemodynamic and Respiratory Variations During Laparoscopic Surgery With and Without Deep Neuromuscular Blockade.
NCT02025075
Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02035345
Fat Distribution and Glucose Metabolism in Williams Syndrome
NCT01864304
Pilot Study of GVAX in Colorectal Cancer Cells
NCT01952730
Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma
NCT01961778
Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT
NCT01825213
Photometric Stereo Endoscopy (PSE) as a Tool for Imaging the Rectum and Colon
NCT01979458
Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome
NCT02004158
An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
NCT01873729
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01961765
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.